Nasdaq:US$15.04 (-0.07) | HKEX:HK$23.22 (-0.20) | AIM:£2.25 (-0.04)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors